Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mylan Confident On Advair Generic First-Round Approval

Executive Summary

President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.

Advertisement

Related Content

Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Teva Advancing Two Advair Generics With Late 2017 Target
Deal Watch: Mylan Counts On A Renaissance For Expansion
Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
US Patent Board To Review Mylan's Copaxone Challenge

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register